Treatment of CNS Tuberculosis in Immunocompromised Adults

Initial Treatment Regimen

The American College of Physicians recommends initiating a 12-month regimen of rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months, followed by rifampicin and isoniazid for 10 additional months, plus adjunctive corticosteroids tapered over 6-8 weeks in immunocompromised adults with CNS tuberculosis 1, 2

The Infectious Diseases Society of America suggests performing CT head scan before lumbar puncture in patients with known severe immunocompromise to assess for mass effect 2
The Centers for Disease Control and Prevention recommend obtaining MRI as soon as possible in all immunocompromised patients with suspected CNS tuberculosis 2
The World Health Organization notes that CSF may be acellular despite active infection in immunocompromised patients, so perform CSF investigations for microbial pathogens regardless of cell count 2

The American Thoracic Society recommends administering four drugs daily, including rifampicin, isoniazid, pyrazinamide, and ethambutol, for the first 2 months of treatment 1, 3
The European Respiratory Society suggests that the total treatment duration must be 12 months for CNS tuberculosis, not the 6 months used for pulmonary TB 1, 2

The National Institutes of Health recommend that all patients with CNS tuberculosis should receive corticosteroids regardless of disease severity 5, 1, 2
The British Infection Association suggests using dexamethasone 12 mg/day for 3 weeks, then taper gradually over the following 3 weeks (total 6 weeks) 2

The Centers for Disease Control and Prevention recommend using the same standard four-drug regimen for 12 months in HIV-infected patients 2
The World Health Organization suggests avoiding highly intermittent regimens (once or twice weekly) in patients with CD4+ counts <100 cells/mm³ due to increased risk of rifampin resistance 7, 2

The Infectious Diseases Society of America recommends performing repeated lumbar punctures to monitor CSF cell count, glucose, and protein changes, especially early in therapy 6, 2
The American College of Physicians suggests monthly clinical assessment for signs of hepatotoxicity (nausea, vomiting, abdominal pain, jaundice) during the first 2 months 2

The European Respiratory Society recommends adding a later-generation fluoroquinolone (moxifloxacin or levofloxacin) to rifampicin, ethambutol, and pyrazinamide for 6 months in cases of isoniazid-resistant disease 3
The American Thoracic Society suggests treating rifampicin-resistant disease with 18 months total: 2 months of isoniazid, pyrazinamide, and ethambutol, followed by 16 additional months of isoniazid plus ethambutol 3

The National Institutes of Health recommend prompt neurosurgical referral for hydrocephalus failing medical management, tuberculous cerebral abscess, and spinal cord compression 5, 2